Home » Newsletters » BioWorld Science

BioWorld Science

April 13, 2012

View Archived Issues

New vaccine shows promise to treat drug addiction

Santaris Pharma identifies new candidate gene therapies for cancer

Novel antibacterials presented by MicuRx Pharmaceuticals

U.S. university patents new histone demethylase inhibitors

Anacor develops novel antibacterial and antimycobacterial agents

New potential therapies for HIV infection reported by Roche

Investigation at Novartis yields novel ENaC antagonists

Novel PFK/FBPase inhibitors divulged by Kancera

Zannan and AB Pharma develop novel highly potent HCV NS3/NS4A inhibitor

Small ApoA-I mimetic is atheroprotective and can be used to image atherosclerotic plaques

New potential oral cancer therapy developed in Korea

Novel thiazolidinediones created in Brazil

Promising first clinical results reported on Affimed TandAb

Veles Pharma prepares innovative drugs for launch

Effective antiviral biosimilar immunotherapy produced by iBioLaunch technology

Arteriocyte obtains FDA clearance for compartment syndrome trial

Joint research for metabolic disease therapies advances

Bayer HealthCare submits new MAA for Xarelto

Agreement seeks to develop companion diagnostic for Adcetris

Novel anti-infectives disclosed by State University of New Jersey

AnGes and BioLeaders enter agreement on oral vaccine for hypertension

Alchemia provides update on pivotal HA-irinotecan trial

AstraZeneca and DNDi enter drug screening collaboration

Shire signs new acquisition agreement

OPKO Health kicks off phase III program for rolapitant

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 13, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
GWAS identifies variant associated with diabetic retinopathy and susceptibility to T2D
BioWorld Science
Scientists at the University of Nottingham Ningbo China and collaborators aimed to identify genetic variants associated with diabetic retinopathy.